Skip to main content

and
  1. No Access

    Article

    Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients

    Trastuzumab-containing neoadjuvant chemotherapy achieves a pathologic complete response (pCR) rate of about 40 % in HER2-positive breast cancers, and pCR predicts better survival. A cohort of 102 consecutive C...

    Guo-Chun Zhang, Xue-Ke Qian, Zi-Bai Guo, Chong-Yang Ren, Meng Yao in Medical Oncology (2012)